Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC8073 | Pyraclonil |
| Pyraclonil is a herbicide agent. | |
| BCC8078 | 8-Bromo-cAMP, sodium salt |
| Cell-permeable cAMP analog; activator of protein kinase A. Also available as part of the PKA. | |
| BCC8079 | Dibutyryl-cAMP, sodium salt |
| Cell-permeable analog of cAMP; activates cAMP-dependent protein kinases. Promotes differentiation of dopaminergic neurons (iDA) from hPSCs in combination with other reagents. | |
| BCC8081 | cAMPS-Sp, triethylammonium salt |
| Cell-permeable cAMP analog that activates cAMP receptor proteins such as PKA and cAMP-regulated guanine nucleotide exchange factor. Enantiomer cAMPS-Rp, triethylammonium salt also available. | |
| BCC8084 | cGMP Dependent Kinase Inhibitor Peptide |
| Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by PKG. Inhibits phosphorylation of intact histones by PKA. | |
| BCC8086 | SL 0101-1 |
| Selective inhibitor of ribosomal S6 kinase (RSK) (IC50 = 89 nM for RSK2). Does not inhibit upstream kinases such as MEK, Raf and PKC. Inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line. | |
| BCC8087 | PKI 14-22 amide, myristoylated |
| Cell-permeable version of protein kinase inhibitor PKI (14-22) amide. The non-myristoylated version inhibits protein kinase A (Ki = 36 nM), inhibits cell growth and induces apoptosis in human pancreatic cancer cells (PANC-1). | |
| BCC8089 | BI 78D3 |
| Competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes. | |
